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The cytotoxic eﬀects of alkylating agents are strongly attenuated by cellular DNA repair processes, necessitating a clear
understanding of the repair mechanisms. Simple methylating agents form adducts at N-a n dO-atoms. N-methylations are
removed by base excision repair, AlkB homologues, or nucleotide excision repair (NER). O6-methylguanine (MeG), which can
eventually become cytotoxic and mutagenic, is repaired by O6-methylguanine-DNA methyltransferase, and O6MeG:T mispairs
are recognized by the mismatch repair system (MMR). MMR cannot repair the O6MeG/T mispairs, which eventually lead to
double-strand breaks. Bifunctional alkylating agents form interstrand cross-links (ICLs) which are more complex and highly
cytotoxic. ICLs are repaired by complex of NER factors (e.g., endnuclease xeroderma pigmentosum complementation group F-
excisionrepaircross-complementingrodentrepairdeﬁciencycomplementationgroup1),Fanconianemiarepair,andhomologous
recombination. A detailed understanding of how cells cope with DNA damage caused by alkylating agents is therefore potentially
useful in clinical medicine.
1.Introduction
Alkylating drugs are the oldest class of anticancer drugs
still commonly used; they play an important role in the
treatment of several types of cancers [1]. Most alkylating
drugs are monofunctional methylating agents (e.g., temo-
zolomide [TMZ], N-methyl-N -nitro-N-nitrosoguanidine
[MNNG], and dacarbazine), bifunctional alkylating agents
such as nitrogen mustards (e.g., chlorambucil and cyclo-
phosphamide), or chloroethylating agents (e.g., nimustine
[ACNU], carmustine [BCNU], lomustine [CCNU], and
fotemustine).
SimplemethylatingagentsformadductsattheN-andO-
atoms in DNA bases. N-methylation adducts comprise more
than80%ofmethylatedbases.ThesealkylDNAbaseadducts
exhibit diﬀerent stabilities. For example, N7-methylguanine
(N7MeG) is the most stable N-methylation adduct in vitro
with a half-life (t1/2) no longer than 80h [2]. Although
O6-methylguanine (O6MeG) accounts for only 0.3% (for
methyl methanesulfonate) to 8% (for methylnitrosourea) of
the total DNA methyl adducts, it is stable and persists in
the absence of the DNA repair protein O6-methylguanine-
DNA methyltransferase (MGMT) [3–5]. O4-methylthymine
(O4MeT) is produced at a much lower level (<0.4%)
[2], and its mutagenicity and cytotoxicity are unclear. In
general, O-alkylations (e.g., O6alkylG and O4alkylT) are
highlymutagenicandgenotoxic,whereasN-alkylations(e.g.,
N3alkylA and N1alkylA) are cytotoxic, but less mutagenic
[6–9]. The primary products of methylating agents, N-
alkylated purines, are eﬃciently removed by base excision
repair (BER) or human AlkB homologues (hABH). BER
repairsN7MeG, N3MeA,andN3MeG,whereashABHrepairs
N1MeA, N3MeC, N3MeT, and N1MeG [10].
One-step repair of O6MeG involves transferring the alkyl
group from the oxygen in the guanine to a cysteine residue
in the catalytic pocket of MGMT [10]. Nucleotide excision
repair (NER) is an elaborate repair system that removes
bulkylesionsfromDNAin27-ntto29-ntoligomers.Because
it is also capable of removing nonbulky lesions such as
apurinic/apyrimidinic sites and O6MeG residues, NER plays2 Journal of Nucleic Acids
ab a c k u pr o l ef o ro t h e rr e p a i rs y s t e m s[ 11]. Mismatch repair
(MMR) is also important in the repair of O6MeG. If it is
left unrepaired, replication over the O6MeG results in an
O6MeG:T mismatch or O6MeG:C ambiguous pair [12]. In
the next round of replication, the O6MeG:T becomes an A:T
transitionmutation,ortheO6MeG:Cisreplicatedagainasan
O6MeG:C pair or becomes an O6MeG:T mismatch [13]. The
O6MeG:T or O6MeG:C is recognized by the MutSα complex
(hMSH2 and hMSH6), which initiates MMR to create a
gapped duplex by incision of the newly replicated strand
[13]. If O6MeG remains in the template, a futile repair
loop can eventually result in highly toxic double-strand
breaks (DSBs), which are intermediates in apoptotic and
DSB repair pathways [13]. Accordingly, DSB repair pathways
are activated by methylating agents [14, 15].
Bifunctional alkylating agents, such as chlorambucil or
BCNU, are commonly used anticancer drugs. DNA lesions
produced by these agents require complex repair mecha-
nisms. The primary chloroethyl adducts at O6G are repaired
by MGMT, but the secondary interstrand cross-links (ICLs)
require NER factors (e.g., endnuclease xeroderma pig-
mentosum complementation group F-excision repair cross-
complementing rodent repair deﬁciency complementation
group 1 (XPF-ERCC1)) for incision, Fanconi anemia (FA)
repair, and homologous recombination (HR) for complete
repair [16].
This paper will focus on the repair pathways for O6MeG
generated by methylating agents and those for ICLs gener-
ated by bifunctional alkylating agents. We will also brieﬂy
discuss other alkylation damage defense and processing
functions (hABH and BER).
2. DNA RepairMechanisms for
DNA Damage Inducedby MethylatingAgents
2.1. MGMT (Figure 1(a)). MGMT repairs O6-alkylation
adducts but irreversibly inactivates MGMT itself in the
process. In the absence of active MGMT, O6MeG forms
O6MeG/T mismatches during replication. Early studies
demonstrated that MGMT-deﬁcient cells unable to repair
O6MeG damage were more sensitive to the eﬀects of methy-
lating agents than normal cells expressing MGMT [17]. This
observationhasbeenutilizedexperimentallyandclinicallyto
target cells with an MGMT inhibitor, the O6MeG analogue
O6benzylG [18]. However, in some tumors, p53 dysfunction
suppresses MGMT expression [19, 20] or hypermethylation
of the MGMT promoter results in gene silencing [21]. The
low basal MGMT activity makes these cells less vulnerable
to the eﬀects of O6benzylG. Kaina et al. reported that about
5% of all solid tumors assayed in their laboratory were
completely deﬁcient in MGMT [10]. In particular, 17% to
30%ofgliomaslackMGMT[22,23].Becausedrugeﬃcacyis
likelytobelimitedifonlyMGMTistargetedinthesetumors,
new molecular targets are being sought.
2.2.MMR(Figure1(b)). Thecytotoxicityofmonofunctional
alkylating agents requires a functional MMR in the target
cells. In fact, mammalian cells proﬁcient in MMR are
generally about 100-fold more sensitive to alkylating agents
than their MMR-deﬁcient counterparts [24, 25]. In MMR-
deﬁcientcells,DNAdamageaccumulatesbutdoesnottrigger
cell death. Thus, resistance to these cytotoxic agents is
associated with loss of MMR activity, particularly in the
absence of MGMT [26, 27]. The mechanism of action of
monofunctional alkylating agents has been studied in cell
lines and mouse models; results indicate that replication
over unrepaired O6MeG:C results in an O6MeG:T mismatch
(or possibly an O6MeG:C ambiguous pair). In the next
round of replication, an O6MeG:T mismatch becomes an
A:T transition mutation. An O6MeG:T or O6MeG:C pair is
recognized by the MutSα complex, which initiates MMR.
MMR creates a gapped duplex after incision of the newly
replicated strand. The mere presence of MeG in the genomic
DNA of MMR-proﬁcient cells is not cytotoxic, even if the
cells are allowed to undergo a round of replication during
which MeG:C and MeG:T pairs form. To activate the G2/M
DNA damage checkpoint, these mispairs must be recognized
and processed. Cells treated with MNNG are not arrested
in the ﬁrst G2/M checkpoint, but G2/M arrest is commonly
observed in the second cell cycle [28].
2.3. DSB Repair (Figure 1(c)). Although alkylating agents do
notdirectlyinduceDSBs,DSBsaredetectedinwild-typecells
and other cell culture systems after the processing of DNA
lesions induced by alkylating agents [14, 15, 29, 30]. DSBs
lead to cell death; therefore, cells defective in DSB repair are
thought to be more sensitive to alkylating agents. Consistent
with this hypothesis, studies have reported that DSB repair
pathways are involved in the repair of DNA damage induced
by alkylating agents [14, 15, 29].
DSBs are repaired through the HR and nonhomologous
end joining (NHEJ) pathways [31]. In human cells, HR
proteins include members of the MRN complex, which
consist of meiotic recombination 11 (MRE11)/radiation-
sensitive mutant 50 (Rad50)/Nijmegen breakage syndrome
1( N B S 1 )a sw e l la sR a d 5 1 ,t h eR a d 5 1p a r a l o g s( R a d 5 1 B ,
Rad51C, Rad51D, X-ray repair cross-complementing group
2 (XRCC2), and XRCC3), Rad54, and Rad54B [31]. Proteins
involved in the NHEJ pathway include Ku70/80, the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs),
ligase IV (Lig4), XRCC4 and Artemis [31].
HR, which is a generally error-free pathway, uses DNA
homology to direct DNA repair; an undamaged chromatid
serves as template for the repair of a broken sister chromatid.
The products of the breast cancer susceptibility genes,
BRCA1 and BRCA2 (also known as FA complementation
group D1 or FANCD1), are also involved in the HR pathway
[32].
HR is required for MNNG-treated cells to transition into
thesecondcellcycle.Mostmammaliancellsthatundergocell
cycle arrest after the second S phase die; however, the surviv-
ing cells show a high frequency of sister chromatid exchanges
(SCEs),indicativeofDSBrepairatcollapsedreplicationforks
[33]. Roos et al. reported that BRCA2/XRCC2-dependent
HR, but not NHEJ, protects against O6MeG-triggered DSBs
and chromosomal aberrations, leading to SCEs [14].Journal of Nucleic Acids 3
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Figure 1: Pathways for DNA damage induced by methylating agents. (a) O6-methylguanine-DNA methyltransferase (MGMT) removes
the methyl adduct from O6MeG in one step. If left unrepaired, O6MeG:C ambiguous pairs or O6MeG:T mismatch pairs can form during
replication. In the next round of replication, O6MeG:T pairs can become A:T transition mutations. (b) O6MeG:T and O6MeG:C pairs are
recognized by the mismatch repair (MMR) system, which creates a single-strand break (SSB), cause replication arrest, and ﬁnally leads to
a double-strand break (DSB). O6MeG:T/C does not induce cell cycle arrest at the ﬁrst G2/M DNA damage checkpoint, but G2/M arrest is
commonly observed in the second cell cycle. (c) Homologous recombination (HR) and nonhomologous end joining (NHEJ) may play a role
in the repair of DSBs. N-alkylations are repaired by either (d) base excision repair (BER), or (e) AlkB homologues, and if not repaired, DSBs
occur.
NHEJ, whichis the simplest wayto repair a DSB, involves
the religation of broken DNA ends without a template;
this type of repair does not preserve the original genetic
information. NHEJ eliminates DSBs during the G1 phase of
the cell cycle, when the lack of sister chromatids prevents HR
[34].
Results of a clonogenic survival study showed that Lig4
plays a more important role in the repair of TMZ-induced
DSBs than XRCC2 or Rad54 [15]. DSBs, which may arise
from adducts other than O6MeG, such as TMZ-induced N-
methylpurines, are repaired within 24h in Lig4-proﬁcient
cells. In contrast, up to 80% of the DSBs in Lig4−/− cells
were not repaired [15]. In A172 glioblastoma cells, siRNA
silencing of Lig4 increased cellular sensitivity to TMZ. After
TMZ treatments, A172 cells with silenced Lig4 exhibited a
62.5%decreaseinsurvivalcomparedwithcontrolA172cells;
thus,modulatingLig4activitymayenhancetumorsensitivity
to TMZ [15].
2.4. BER (Figure 1(d)). The alkylation adducts N7MeG,
N3MeA, and N3MeG are repaired by the BER system,
the main DNA repair system in mammalian cells used to
eliminate small DNA base lesions [16]. Damaged bases are
removed by a lesion-speciﬁc DNA glycosylase, in this case
alkyladenine DNA glycosylase (Aag). The resulting abasic
site is recognized by an apurinic/apyrimidinic endonuclease,
APE1, which incises the damaged strand, leaving 3 -OH and
5 deoxyribose phosphate (5 -dRP) groups at the margins.
AD N Ap o l y m e r a s eβ-( p o l - β-)mediated DNA synthesis
step ﬁlls the single nucleotide gap [35, 36]a n dr e m o v e s
the cytotoxic 5 -dRP group [37, 38]. Alternatively, DNA
polymerase λ (pol-λ) or DNA polymerase-ι (pol-ι), both of
which possess 5 -dRP lyase activity, may participate in BER
to remove this toxic repair intermediate [39–41]. Finally,
DNA ligase I, or a complex of DNA ligase III and XRCC1,
conducts the ﬁnal, nick-sealing step in the pathway [42].
In the absence of pol-β, cells cannot repair the BER
intermediate 5 dRP and are thus hypersensitive to the
alkylating agent methyl methanesulfonate [37, 38, 43, 44].
For example, ﬁbroblasts from a pol-β-null mutant mouse
are highly sensitive to monofunctional alkylating agents, but
not to BCNU [45]. Similarly, RNA interference-mediated
pol-β suppression boosts TMZ eﬃcacy, although a deﬁ-
ciency in pol-ι or pol-λ does not increase TMZ-mediated
cytotoxicity [46]. Furthermore, loss of pol-β coupled with
TMZ treatment triggers H2AX phosphorylation, indicating
activation of the DNA damage response pathway by unre-
paired lesions [46]. H2AX is a histone protein that is rapidly
phosphorylated on Ser139 (γH2AX) when DNA breaks are
introduced in mammalian cells following external damage
and replication fork collapse [47, 48]. Poly(ADP-ribose)
polymerase-1 (PARP-1) is activated by strand breaks and
participates in gap sealing with DNA ligase III and XRCC1,
but deﬁciencies in the subsequent steps of BER increase
sensitivity to alkylating agents. Inhibition of PARP-1 by the
inhibitor AG14361 restores sensitivity to TMZ in MMR-
deﬁcient cells that have lost killing sensitivity to O6MeG via
the MGMT/MMR pathway [49]. The combination of TMZ
with PARP-1 inhibitors is currently under investigation in
several Phase I-II clinical trials.4 Journal of Nucleic Acids
2.5.DirectReversalof AlkylationDamagebyAlkBHomologues
(Figure 1(e)). The E. coli protein AlkB is an oxidative
DNA demethylase that repairs the cytotoxic lesions N1MeA
and N3MeC. A detailed mapping of the human genome
has identiﬁed eight hABH homologues. ABH2 and ABH3
belong to the alpha-ketoglutarate- and Fe(II)-dependent
dioxygenase superfamily. These proteins repair N1MeA,
N3MeC, N3MeT, and N1MeG by oxidative demethylation
[50, 51]. Although hABH2 preferentially repairs double-
stranded DNA, hABH3 acts more eﬃciently on single-
stranded nucleic acids. Accordingly, hABH2 relocates to
replicationfociduringS-phase,whichsuggestedthathABH2
repairs DNA close to replication forks, whereas hABH3
maintains nuclear single-stranded DNA and RNA, poten-
tially targeting genes undergoing transcription.
3. Repair of Cross-links Inducedby
BifunctionalAlkylatingAgents
Bifunctional alkylating agents (e.g., nitrogen mustards (mel-
phalan, chlorambucil, cyclophosphamide, and ifosfamide)
and chloroethylnitrosoureas (BCNU and CCNU)) possess
two reactive sites. These agents cross-link DNA with proteins
or, alternatively, cross-link two DNA bases within the same
DNA strand (intrastrand cross-links) or on opposite DNA
strands (ICLs). ICLs, which block replication forks, are the
mostseriouscytotoxiclesionsproducedbymostbifunctional
drugs.Accordingly,theextentofICLscorrelateswellwiththe
cytotoxicity of nitrogen mustard drugs [52].
Nitrogen mustards form N7G:N7G cross-links, and
chloroethylnitrosoureas form N1G:N3C cross-links [53].
The chloroethylated O6G of the N1G:N3C cross-link can
be repaired by MGMT; however, this adduct is unstable
and undergoes intramolecular rearrangement producing an
intermediary N1-O6-ethanoG. The N1-O6-ethanoG adduct
mayreactwithcytosineinthecomplementarystrandtoyield
a highly toxic ICL between position 1 in the guanine residue
and position 3 in the cytosine residue (1-(3-cytosinyl)-2-(1-
guanosinyl)-ethane) [53].
ICL repair mechanisms are complex; therefore, they
are only brieﬂy summarized here. An ICL represents a
formidable block to the DNA replication machinery and
is unique in requiring a combination of FA repair, NER,
translesionsynthesis(TLS),andHRrepairforeﬃcientrepair
[54]. Although the FA pathway was initially characterized
in terms of DNA cross-link repair, this pathway is also
involved in homologous recombination and resolution of
the replication arrest [55, 56]. Thirteen FA genes have
been identiﬁed [54], although the precise function of many
of these FA proteins is unclear. The FA core complex,
which consists of eight FA proteins, is activated by DNA
damage. Speciﬁcally, the FA proteins FANCM and FANCA
Associating Polypeptide 24 form a heterodimer that binds
DNA [57, 58] and appears to be involved in sensing DNA
replication forks blocked at cross-links. The NER proteins
ERCC1 and XPF make incisions on either side of the cross-
link to generate a gap. The gap is then ﬁlled by translesion
synthesis (TLS) polymerases ζ (Rev3 and Rev7 subunits)
and Rev1 (part of the Rev3-Rev7 complex [59]). The FA
core complex monoubiquitinates FANCD2 and its paralog
FANCI, and the ubiquitinated FANCD2 then interacts with
FANCD1 to promote HR [54].
Incision at the ICL could occur before or after lesion
bypass, leaving a DSB subject to HR or NHEJ [60]. As
expected, XRCC2 and Rad54 are involved in the repair of
ACNU-induced DSBs, but surprisingly Lig4 plays the most
important role in this process [29]. In Lig4−/− cells, levels of
phosphorylated histone γH2AX increased more than 4-fold
at 12h and 6-fold at 24h after ACNU treatment compared to
its initial levels. In contrast, γH2AX levels were not markedly
altered by ACNU in normal cells. In addition, ACNU
treatment markedly reduced the colony-forming ability of
A172 glioblastoma cells transfected with siRNA against Lig4
or XRCC2 compared to controls [29]. However, Lig4 siRNA
rendered cells more sensitive to the eﬀects of ACNU than did
XRCC2 siRNA [29]. These data suggest NHEJ may also be
involved in removing DSBs formed by unrepaired ICLs.
4. Conclusion
DNA repair pathways attenuate the therapeutic eﬀects of
alkylating agents; therefore, characterization of the repair
pathways is essential for developing new treatments. For
example, MGMT promoter hypermethylation results in gene
silencing and therefore decreased MGMT activity; therefore,
MGMT promoter hypermethylation may be a useful way to
enhance the therapeutic eﬃcacy of TMZ [61, 62].
Currently, clinical trials are testing DNA repair inhibitors
that target PARP, BER, or MGMT in combination with
alkylating agents [63]. In the case of O6benzylG, a phase I
clinical trial has deﬁned the maximum tolerated dose of a
single dose of TMZ when combined with O6benzylG and
has determined the dose of O6benzylG that depletes tumor
MGMT activity for 48h [64]. In addition, when combined
with cytotoxic chemotherapy, myelosuppression appears
to be signiﬁcantly enhanced by O6benzylG, signiﬁcantly
reducing the required doses of alkylating agents [65]. The
success of such approaches will depend on selective targeting
of the tumor. Locoregional chemotherapy has recently been
shown to improve the survival of glioma patients [66].
Therefore, combining a locoregional delivery system with
the simultaneous downregulation of DNA repair pathways
may decrease the amount of alkylating agent needed for
chemotherapy, thereby reducing the severe side eﬀects. In
addition, new inhibitors against speciﬁc repair proteins, such
as pol-β, BRCA2, or Lig4, should be developed because
resistance against currently available inhibitors may develop.
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